Skip to main content
Device/Product name
Active Ingredient
Date of decision
Submission type
New chemical entity
ATC codes
Approved for provisional registration
What was the decision based on
The decision was based on quality (chemistry and manufacturing), nonclinical (pharmacology and toxicology), clinical (pharmacology, safety and efficacy) and risk management plan information submitted by the sponsor. The benefit-risk profile of Lumakras was considered favourable for the therapeutic use approved.
What steps were involved in the decision process

Registration timeline

This evaluation was facilitated through Project Orbis, an initiative of the United States (US) Food and Drug Administration (FDA) Oncology Center of Excellence (OCE). Under this project, the FDA, Health Canada (HC) and the TGA collaboratively reviewed the application. This innovative evaluation process provided a framework for process alignment and management of evaluation issues in real-time across jurisdictions.

Each regulator agency maintained its regulatory process to make independent decisions about the approval (market authorisation).

Description Date
Designation (Provisional)
Designation (Orphan)
7 January 2021
10 November 2020
Submission dossier accepted and first round evaluation commenced 1 March 2021
First round evaluation completed 30 July 2021
Sponsor provides responses on questions raised in first round evaluation 31 August 2021
Second round evaluation completed 13 December 2021
Delegate's overall benefit-risk assessment and request for Advisory Committee advice 3 November 2021 and
10 January 2022
Sponsor's pre-Advisory Committee response 16 November 2021 and
24 January 2022
Advisory Committee meeting 2 and 3 December 2021 and
3 and 4 February 2022
Registration decision (Outcome) 28 March 2022
Completion of administrative activities and registration on ARTG 30 March 2022
Number of working days from submission dossier acceptance to registration decision* 244

*Statutory timeframe for standard applications is 255 working days

Date of entry onto ARTG
Original publication date
Black triangle scheme
As a provisionally registered product, this medicine will remain in the Black Triangle Scheme for the duration of its provisional registration.
Dose forms
Film coated tablet
120 mg
Other ingredients
Microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, titanium dioxide, purified talc, iron oxide yellow, polyethylene glycol and purified water
Blister pack
Pack sizes
56 and 240
Routes of administration

The recommended dose of Lumakras is 960 mg (as 8 x 120 mg tablets) orally once daily until disease progression or unacceptable toxicity.

For further information refer to the Product Information.

Pregnancy category
B3Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed.Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans.The use of any medicine during pregnancy requires careful consideration of both risks and benefits by the treating health professional. This must not be used as the sole basis of decision making in the use of medicines during pregnancy. The TGA does not provide advice on the use of medicines in pregnancy for specific cases. More information is available from obstetric drug information services in your State or Territory.
What was approved

Lumakras (sotorasib) was approved for the following therapeutic use:

Lumakras has provisional approval in Australia for the treatment of adult patients with KRASG12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy for advanced disease.

The decision to approve this indication has been made on the basis of the objective response rate (ORR) and the duration of response (DOR). Continued approval of this indication depends on the verification and description of benefit in confirmatory trials.

What is this medicine and how does it work
Sotorasib is a Kirsten rat sarcoma (KRAS)G12C inhibitor, which covalently and irreversibly binds to the unique cysteine of KRASG12C. Inactivation of KRASG12C by sotorasib blocks tumour cell signalling and survival, inhibits cell growth, and promotes apoptosis selectively in tumours harbouring KRASG12C, an oncogenic driver of tumourigenesis across multiple cancer types. The potency and selectivity of sotorasib is enhanced through the unique binding to both the P2 pocket and the histidine 95 (His95) surface groove, locking the protein in an inactive state that prevents downstream signalling without affecting wild-type KRAS.Sotorasib demonstrated in vitro and in vivo inhibition of KRASG12C with minimal detectable off target activity against other cellular proteins and processes. Sotorasib impaired oncogenic signalling and tumour cell survival at clinically relevant exposures in preclinical models expressing KRASG12C. Sotorasib also enhanced antigen presentation and inflammatory cytokine production only in tumour cells with KRASG12C. Sotorasib induced anti tumour inflammatory responses and immunity, driving tumour regressions in immunocompetent mice implanted with KRASG12C expressing tumours.
What post-market commitments will the sponsor undertake
  • Lumakras (sotorasib) is to be included in the Black Triangle Scheme. The Product Information (PI) and Consumer Medicines Information (CMI) for Lumakras must include the black triangle symbol and mandatory accompanying text for the products entire period of provisional registration.
  • The Lumakras European Union (EU) risk management plan (RMP) (version 0.2, dated 25 June 2021, data lock point 1 September 2020), with Australian specific annex (version 2.0, dated 18 August 2021), included with Submission PM 2021 00026 1 4, and any subsequent revisions, as agreed with the TGA will be implemented in Australia.

    Unless agreed separately between the supplier who is the recipient of the approval and the TGA, the first report must be submitted to TGA no later than 15 calendar months after the date of the approval letter. The subsequent reports must be submitted no less frequently than annually from the date of the first submitted report until the period covered by such reports is not less than three years from the date of the approval letter, or the entire period of provisional registration, whichever is longer.

    The reports are to at least meet the requirements for periodic safety update reports (PSURs) as described in the European Medicines Agency's guideline on Good Pharmacovigilance Practices (GVP) Module VII periodic safety update report (revision 1), Part VII.B structures and processes. Note that submission of a PSUR does not constitute an application to vary the registration. Each report must have been prepared within ninety calendar days of the data lock point for that report.

  • Confirmatory trial data (as identified in the sponsor's plan to submit comprehensive clinical data on the safety and efficacy of the medicine before the end of the 6 years that would start on the day that registration would commence) must be provided.

    Specifically, the sponsor must conduct studies as described in the clinical study plan in version x 2.0 (dated 18 August 2021) of the Australia specific annex.

    The following study report should be submitted to TGA:

    • Study 20190009 by 28 March 2028
  • Sponsor to conduct and submit results of a multi center, randomised clinical trial to further characterise serious adverse events, including gastro intestinal toxicity and compare the safety and efficacy of sotorasib 960 mg daily versus a lower daily dose in patients with locally advanced or metastatic, KRASG12C mutated, non-small cell lung cancer who have received at least one prior systemic therapy.
  • Sponsor to conduct and submit results of a hepatic impairment clinical trial to determine a safe and appropriate dose of sotorasib in patients with moderate and severe hepatic impairment. Design and conduct the trial in accordance with the Food and Drug Administration (FDA) guidance for industry titled 'Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling'.
  • Sponsor to conduct and submit results of a clinical drug interaction study to assess the effect of concomitant sotorasib administration on the systemic exposure of Breast Cancer Resistance Protein (BCRP) transporter substrates. Refer to FDA guidance for industry for additional details: 'Clinical Drug Interaction Studies - Cytochrome P450 Enzyme and Transporter Mediated Drug Drug Interactions.'
  • Sponsor to conduct and submit results of clastogenicity studies (to be assessed by an in vitro or in vivo clastogencity study, preferably by in vivo chromosome aberration assay) of impurities [Studies] 3379613, 3379620, 3368167, 3396902, 3412607, 3413168, 3422551, 3422536 and 3422547; these results will need to be submitted before full registration of sotorasib is granted.

Help us improve the Therapeutic Goods Administration site